Abstract
As is true for many pediatric illnesses, the treatment of hypertension in childhood has been hampered by a paucity of data regarding antihypertensive drug pharmacokinetics and efficacy in children. Although nearly all antihypertensive agents have been used to treat hypertensive children,1 until recently only a few of these agents had been systematically studied in children, and few drug manufacturers included pediatric dosing recommendations in their published prescribing information.2 If a physician wishes to use a new drug or a drug without a manufacturer's pediatric dose recommendation, he or she must adapt adult doses, a practice that is fraught with numerous potential problems.3 Hypertensive children in need of pharmacologic treatment could truly be considered “therapeutic orphans,”3,4 with each prescription written an experiment with a single subject.